Considered for Treatment of patients with platinum-resistant high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received at least one prior systemic treatment regimen and have high folate receptor alpha (FRα) tumour cell expression (≥75% of viable tumour cells with moderate [2+] and/or strong [3+] membrane staining).
PBAC outcome
—
Authority Required
ICER (AUD/QALY)
Redacted
commercial-in-confidence
Submissions
1
first 2025
Submissions
1
2025 → 2025
Eligible population
Patients with platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received at least one prior systemic treatment regimen and have high FRα tumour cell expression (≥75% of viable tumour cells with moderate [2+] and/or strong [3+] membrane staining) as determined by immunohistochemistry (IHC) testing.
Therapy area
Oncology
Line of therapy
Second-line
Evidence base
RCT
Primary endpoint
OS
Key trials
MIRASOL
Comparator
non-platinum chemotherapy (paclitaxel, topotecan, or pegylated liposomal doxorubicin) with or without bevacizumab
Economic model
CUA
ICER note
ICER values are redacted in the public summary document (shown as $ symbols)